Impact of Home Hospitalization on the Cost of Care for 1ST Line Treatment of Locally Advanced or Metastatic HER2+ Breast Cancer

Author(s)

Benyounes K1, Le Lay K1, Roula A2, Rousseau M1, Eyraud R1, Chamielec C3, Tehard B4
1Roche, Boulogne-Billancourt, France, 2Roche, Boulogne-Billancourt, 75, France, 3Vyoo Agency, Paris, France, 4Vyoo Agency, Paris, 75, France

OBJECTIVES: Anti-HER2 targeted therapies are the standard of care for first line treatment locally advanced or metastatic HER2+ breast cancer. In France, these treatments are mainly administered at hospital while at home hospitalization, less costly, could be organized leading to structural savings for healthcare system.

METHODS: A cost model was used to estimate the cost of an episode of care with anti-HER2 targeted therapy fully administered at hospital vs full home hospitalization for a patient with a locally advanced or metastatic HER2+ breast cancer. The episode of care is based on real life practice database PRM (Personalized Reimbursement Model) that follows treatments’ administration of HER2+ breast cancer patients in France. The model focuses on administration costs and transportation costs that drive the difference of management between day hospitalization and home hospitalization. The costs are valued from a health insurance perspective. The costs of treatment administration were calculated from the current French tariff model and the National Cost Studies.

RESULTS: From a health insurance perspective, the average tariff of a day hospitalization administration, identified from the public and private hospital tariffs of the diagnosis-related group was €368.47. The average tariff of a home hospitalization administration, identified from the public and private hospital tariffs of the French model corresponding to 3 homogeneous groups of care, was €263.02 for day and home hospital treatment administration respectively. An additional €39.05 transportation cost was considered for hospital administration.

For a given patient, over a 5-year time horizon, with an average treatment duration of 14.4 months, a day hospital-based care management of €17,513 vs a home hospital-based care management of €12,406 were estimated, representing an individual average €5,107 saving (29.2%).

CONCLUSIONS: Home hospital-based care management of HER2+ breast cancer represents a promising cost-saving opportunity for healthcare insurance that could also relieve hospitals already overloaded in France.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

EE36

Topic

Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory

Topic Subcategory

Public Health, Public Spending & National Health Expenditures

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×